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Site and mechanism of enhanced gastrointestinal absorption of alumi-
num by citrate. Clinical and experimental studies have shown that
citrate markedly enhances the intestinal absorption of aluminum (Al),
but the site and mechanism of enhanced absorption are unknown. To
determine where in the gastrointestinal tract aluminum citrate (Alcitr)
was absorbed, Alcitr was gavaged with D-[l-3H] glucose in male
Sprague-Dawley rats. Plasma Al levels increased rapidly and simulta-
neously peaked with D-[1-3G1 glucose, suggesting early proximal bowel
absorption. In in vitro duodenal and jejunal everted gut preparations,
Alcitr incubation resulted in increased tissue Al levels and markedly
enhanced transmural transport of Al and citr. Unlike citr, the transmu-
ral movement of Al was independent of temperature (37°C vs. 4°C). On
the other hand, Al lactate (al Lac) increased tissue associated Al levels
but had no effect on transmural Al movement. To determine if this large
flux of Al following Alcitr administration was due to paracellular
movement, ruthenium red and Ussing chamber studies were used to
evaluate the morphologic and functional integrity of cellular tight
junctions. Alcitr, as opposed to AId3, markedly increased ruthenium
red deposits in intercellular spaces, especially around goblet cells, and
induced a prolonged significant reduction in transmural resistance.
Alcitr also resulted in rapid and nearly complete (99.7%) chelation of
free calcium, an event known to disrupt cellular tight junction integrity.
Taken together, these data suggest that enhanced Al absorption follow-
ing administration of Alcitr occurs in the proximal bowel via the
paracellular pathway due to the opening of cellular tight junctions.
There is little information available regarding the factors that
control and modulate the absorption of non-essential and po-
tentially toxic trace elements from the gastrointestinal tract.
One element of recent interest is aluminum, since orally admin-
istered aluminum compounds have been shown to exert toxic-
ity, at least in individuals with compromised renal functions
[1—5]. Attempts to characterize aluminum absorption have been
met with difficulties because a suitable isotope is not available,
and aluminum compounds previously employed formed insolu-
ble hydroxides at a physiological pH [61, which makes the
interpretation of in vitro studies difficult, if not impossible.
Therefore, indirect means of evaluating aluminum absorption,
like change in urinary aluminum or serum or tissue burden of
aluminum following an oral load, have been largely utilized
[7—111. Using these techniques, it would seem that at least four
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factors influence aluminum absorption: the dose of aluminum
administered, the solubility of the aluminum compound, the
uremic state and the concomitant administration of aluminum
compounds with citrate [2, 3, 9, 11, 12—14]. Although other
factors such as parathyroid hormone and vitamin D have been
suggested to affect aluminum absorption, the data available are
largely conflicting and difficult to resolve [9, 15—171.
Citrate may be the most important clinical modulator of
aluminum absorption. It has previously been shown that alumi-
num absorption is increased when a variety of different alumi-
num compounds are administered with several forms of citrate
[18—211, In patients with renal failure, the concomitant admin-
istration of aluminum compounds with citrate has resulted in
extremely high plasma aluminum levels with associated toxicity
[2]. In fact, it would seem that virtually every case of aluminum
toxicity described in nondialyzed uremic children, as well as
adults, has resulted from the combined administration of alu-
minum-containing phosphate binding gels and Shohl's solution
(sodium citrate) [16, 17].
The present studies, therefore, were carried out to character-
ize the gastrointestinal site of citrate-enhanced aluminum ab-
sorption and to determine the cellular mechanism responsible
for citrate's marked enhancement of aluminum absorption.
Methods
All studies were carried out using male Sprague-Dawley rats
weighing 250 to 350 g (Simonsen-Mill Rendering Plant, Quimby,
Iowa, USA). For the in vivo studies, animals were housed in
metabolic cages (Nalgene) and standard rat chow was with-
drawn 16 hours prior to gastric lavage.
In an attempt to determine if the maximum aluminum absorp-
tion occurred in the proximal part of the small intestine serial
bloods were obtained at timed intervals (0 to 420 mm) following
the gavage of 0.89 mmol/kg of aluminum citrate with 2 p.Ci
D-[l-3H] glucose (Amersham) and 3.3 mmol D-glucose.
Everted gut preparations
Fasting Sprague-Dawley rats were anesthetized with meth-
oxyflurane, and everted gut sacs of 5 cm were prepared
according to a modified technique of Parson, and Wilson and
Wiseman [22, 231. Duodenum (1 cm distal to the pylorus) and
proximal jejunum (8 cm distal to the pylorus) segments were
filled with 0.7 ml of Kreb's bicarbonate solution (Na 135.0, K
0.5, Ca 2.5, Mg 1.2, phosphate 1.0, Cl 121.4, bicarbonate 24,
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glucose 11.5 m with Al less than 0.1 smol). A bicarbonate
buffer was used to resemble the environment of the small
intestine fluid and because aluminum does not form significant
complexes with bicarbonate [24]. The modifications in the
serosal fluid volume were corrected with 3H-polyethylene gly-
col (molecular wt 4,000, New England Nuclear Corporation,
Boston, Massachusetts, USA) [6]. The gut sacs were weighed,
suspended in 50 ml of Kreb's bicarbonate solution containing
370 micromolar of aluminum citrate or 370 sM of aluminum
lactate and incubated for one hour at 37°C or 4°C. A mixture of
95% 02 and 5% CO2 was bubbled through the solution to
maintain oxygenation and a pH of 7.40. Following the incuba-
tion, the gut sacs were removed and gently rinsed in four dishes
of cold Kreb's bicarbonate solution for two minutes. The fluid
contents were then drained with a needle and syringe and the
gut opened, rinsed and processed for tissue aluminum determi-
nation. Aluminum transmural (mucosal-serosal) transport
(change in the total serosal fluid aluminum divided by the wet
weight) and tissue aluminum content were determined. The
everted gut preparation was not done with aluminum chloride
because of its poor solubility due to hydroxide formation at the
pH used [25]. Only preparations with an intact metabolism, as
assessed by a glucose serosallmucosal ratio greater than 1, were
accepted (more than 95% of our preparations). The basal
aluminum contamination of the serosal fluid due to the alumi-
num mucosal bath (concentration of 370 tM) did not exceed 0.6
M and was subtracted from all serosal fluid aluminum deter-
minations. Basal aluminum tissue content was 5 4 pmollmg
wet weight. In some aluminum citrate experiments, the trans-
port of citrate was also measured with the use of aluminum
'4C-citrate. This compound was formed by incubating an excess
of aluminum chloride with '4C-citric acid for one hour (New
England Nuclear Corporation) [26].
Isolated loop with ruthenium red
For the ruthenium red studies, fasting rats under methoxy-
flurane anesthesia had their duodenums exposed by an abdom-
inal incision. A polyethylene catheter was inserted through a
stomach incision and duodenal content flushed with warm
saline. After expelling the residual fluid with air, the distal end
was tied with silk and filled with either 1 ml of aluminum
chloride (18.5 smol per ml) or aluminum citrate (18.5 mol per
ml) in normal saline. Control rats had the instillation of only 1
ml of normal saline. The proximal end was then closed with silk
without comprising the blood circulation and the abdominal
incision was closed. Following a one-hour recovery period, the
rat was anesthetized and its duodenum fluid replaced with 1 ml
of ruthenium red solution (ruthenium red 0.1%, sodium cocody-
late 0.1 M, glutaraldehyde 2%, pH 7.2). The isolated loop, with
both ends tied, was then excised from the rat and fixed in 2%
glutaraldehyde for three hours. The bowel content was then
replaced with sodium cocodylate 0.1 M and ruthenium red 0.1%
and the gut sac was kept overnight at 5°C in a bath of sodium
cocodylate 0.1 M. The following morning the sac content was
replaced with a mixture of 2% osmium tetraoxide, ruthenium
red 0.1% and sodium cocodylate 0.1 M, and the whole prepa-
ration was put in a solution of osmium tetraoxide 2% and
sodium cocodylate 0.1 M for three hours while sheltered from
light. After osmium fixation, the duodenum was rinsed with
distilled water, opened and cut in pieces of 2 mm2.
Following dehydration in graded ethanol solution, specimens
were incubated first for 30 minutes in propylene oxide: ethanol
1:1, then propylene oxide for one hour, and finally they were
stored at 4°C overnight in propylene oxide: ethanol (1:1). The
following day the sections were put in a fresh 100% plastic
solution for three periods of one hour and dried at 60°C
overnight in 100% fresh plastic solution. Ultrathin sections
were then cut and viewed with a Philips CM-l2 electron
microscope.
Ussing chamber
The effect of aluminum citrate on the transmural resistance of
jejunal preparations was studied with a modified Ussing appa-
ratus [27, 28]. Proximal jejunal segments were opened on the
mesenteric border and mounted unstripped on the Ussing
chamber with a tissue aperture of 0.5 square cm. Each
hemichamber contained 10 ml of the same Kreb's bicarbonate
solution described in the everted gut protocol, and was bubbled
with 95% 02 and 5% CO2 at 37°C. Both mucosal and serosal
solutions were connected with agar bridges to calomel elec-
trodes for the direct measurement of the potential difference
(PD) and to Ag-AgC1 electrodes for the passage of a direct
current through the tissue. An automatic dual voltage clamp
(616-C3, Bioengineering, University of Iowa, Iowa, USA) was
used to deliver the current (20 s A2 cm) and to record the PD
and the short circuit current (Isc). Resistance (R) was calcu-
lated from the PD and the Isc and corrected to a surface area of
I square cm. After an equilibration period of 10 minutes of
stability aluminum citrate (N = 5; 18.5 mM) was added to the
mucosal bath (final concentration). Controls (N = 3) consisted
of the same Kreb's bicarbonate solution without the addition of
aluminum. The small increase in osmolality did not affect the
resistance as shown by the absence of significant modifications
with the addition of sodium acetate (55.5 mM). Additional
controls consisted of sodium citrate (N = 3; 55.5 mM) and
EDTA (N = 2; 0.6 mM), two compounds known to open tight
junctions. The volume was kept constant and all solutions were
buffered at a pH of 7.4 at a temperature of 37°C.
Calcium chelation
Aluminum citrate, chloride and lactate, respectively, were
added to a Kreb's bicarbonate solution (pH 7.4 with 95% 02 and
5% C02, 2.25 m of calcium) for a final aluminum concentra-
tion of 18.5 m. Free calcium activity was determined before
and after aluminum load with a calcium electrode [29] (Model
932-00, Orion Research Inc., Boston, Massachusetts, USA) and
a dose-response curve was determined for aluminum citrate.
Analytical determinations
All samples were carefully manipulated to avoid aluminum
contamination. Only plastic containers or Pyrex glass washed
with EDTA were used. Bloods were drawn with EDTA. Deter-
minations of aluminum in plasma, urine, tissue and solutions
were performed on a flameless atomic absorption spectrometer
(Perkin-Elmer 5000, Norwalk, Connecticut, USA) according to
a previously described method [30]. Standard double isotope
techniques were used to quantitate the 3H-polyethylene glycol
and '4C-citrate using a Beckman LS 5801 liquid scintillation
spectrometer (Beckman Instruments, Fullerton, California,
USA). Statistical analysis was performed using a computer
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2). This was in spite of similar solubility of aluminum lactate
and citrate in the incubating medium as determined by the
aluminum content post-incubation. There was no difference in
the final serosal fluid volume between aluminum citrate and
lactate.
The markedly enhanced temperature-independent transmural
movement of aluminum in response to aluminum citrate sug-
gested that citrate, a compound known to open epithelial tight
junctions [311, might have enhanced paracellular aluminum
movement by transiently opening cellular tight junctions. Ru-
thenium red, a low molecular weight, impermeable cell coat
marker [32], was used to evaluate tight junctions structural
integrity. Ruthenium red was applied in the presence of 2%
240 280 glutaraldehyde to the mucosal surface. Its presence in the
intercellular spaces was then used to evaluate the structural
integrity of tight junctions. In control, early intestinal segments
previously exposed to normal saline only, minimal or no
ruthenium red deposits could be visualized between adjacent
epithelial cells (Fig. 2A). The mucosal epithelium was intact and
did not appear to have undergone cellular injury. Incubation
prior to fixation and ruthenium red application with aluminum
citrate resulted in an intense infiltration of ruthenium red
deposits into the paracellular spaces, especially around goblet
cells (Fig. 2B) and was consistent with an opening of the tight
junctions. In fact, entire goblet cells were outlined with ruthe-
nium red (Fig. 2C). Minimal ruthenium red deposits could be
visualized between epithelial cells. Aluminum chloride pre-
incubation resulted in minimal or no ruthenium red localized to
intercellular spaces, but it did cause patchy apical membrane
sloughing (Fig. 2D) which was not seen either with normal
saline or aluminum citrate pre-incubation.
To further characterize the effect of aluminum citrate on tight
junctions functional integrity, the effect of aluminum citrate
(18.5 mM) on transmural resistances of proximal jejunum seg-
ments was studied using modified Ussing chamber techniques.
As is shown in Figure 3, transcellular resistance in control
studies remained stable with a means value of 26 4ohm cm2.
Transcellular resistance decreased rapidly following the addi-
tion of aluminum citrate (18.5 g.tM) and stabilized after 15
minutes of exposure at 19 2 ohm cm2 (P < 0.01). Sodium
citrate (55.5 mM) was used as a positive control and had a
similar effect on the rate of decrease in transcellular resistance
(—9 1, P c 0.01). Neither 55.5 m Na acetate (—2 2 ohm
cm2) nor 18.5 m aluminum chloride (—2 2 ohm cm2) had
any significant prolonged effect on transcellular resistance.
Because of the critical importance of extracellular calcium for
the maintenance of tight junctions and because citrate is known
to chelate calcium, calcium binding ability of different prepara-
tions of aluminum was studied. Aluminum citrate, chloride and
lactate were put in a Kreb's bicarbonate solution gassed with
95% 02 and 5% CO2 with a final concentration of 18.5 mM.
Aluminum lactate did not complex any calcium, and aluminum
chloride complexed only 19.9% of the available calcium (Table
3). Aluminum citrate, on the other hand, complexed almost all
the calcium present (99.7 0.1%) with a ratio of 1.99 0.16
aluminum per calcium (calculated at 50% complex capacity,
Fig. 4). Of interest is that aluminum chloride formed a whitish
compound when put in a pH greater than 3, a phenomenon that
represents the formation of a large, high molecular weight
colloid in association with phosphates and hydroxides [251.
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Fig. 1. Plasma aluminum (0) and D(I-3H) glucose (•) as a percent of
maximum value after gavage of! ml of a solution containing 0.89 mmol
k'body wt of aluminum citrate and 2 nCi of D(i 3H) glucose in a
carrier solution of3.30 m glucose. Both plasma aluminum and D(l-3H)
glucose peaked before 45 mm after gavage. Values represent the mean
sn, N = 3.
statistical pack (Human System Dynamics, Northridge, Califor-
nia, USA). The Mann-Whitney test was used for comparison of
two groups, and Kruskal-Wallis was carried out for comparison
of more than two groups. Results are expressed as mean 1 513
unless otherwise stated.
Initial studies were conducted to determine if citrate caused
an enhancement of aluminum absorption in the proximal small
bowel. Results of in vivo gavage studies are shown in Figure 1.
That aluminum absorption from aluminum citrate did occur in
the proximal small bowel is suggested in Figure 1. 3H-glucose
was used as a marker of early proximal bowel absorption. The
absorption of aluminum minored that of glucose indicating that
it, too, was absorbed in the proximal gastrointestinal tract.
Since plasma aluminum levels returned to baseline values
within 240 minutes while 98% of the aluminum remained in the
gastrointestinal tract [31, this suggests that little aluminum was
absorbed more distally. Because the above studies were con-
sistent with the aluminum citrate being absorbed in the proxi-
mal region of the intestine, evened gut studies were carried out
in the duodenal and jejunal segments. Following incubation
with a luminal medium containing 370 jiM aluminum citrate at
37°C, tissue-associated aluminum content increased from a
baseline of S to 91 27and 115 60 pmol per mg of wet weight
in the duodenum and jejunum, respectively. In contrast, when
the incubation was performed at 4°C, tissue-associated alumi-
num was not different from control baseline value (P = NS;
Table 1). However, aluminum transmural movement, as deter-
mined by the delta in the serosal fluid aluminum, was 60 times
over baseline (P < 0.001) and was temperature independent
(37°C vs. 4°C, P = NS, Table 1). In contrast to aluminum, both
tissue-associated uptake and transmural transfer of citrate were
markedly decreased at 4°C (Table 1). Although tissue-associ-
ated aluminum from aluminum lactate was greatly increased
over that found with aluminum citrate and similarly affected by
cold, there was no transmural transfer into serosal fluid (Table
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Table 1. Transmural transport and tissue-associated aluminum in everted gut preparation
Aluminum Citrate
N Tissue Transport N Tissue Transport
Duodenum 37°C
4°C
12
10
91 27
16 10°
6.63
6.01
3.64
2.15
6
6
432 128
112 33°
493
38
120
11°
Jejunum 37°C
4°C
12
10
115 60
14 9°
9.38
6.38
5.43
2.15
6
6
394 66
106 19°
587
35
189
10°
Results are expressed in picomoles mg weight. Everted gut segments were incubated in a bath containing 370 M of aluminum citrate for one
hour. Segments were washed and their content aspirated with a syringe for aluminum determination.
aP < 0.001 between 37°C and 4°C; P = NS between jejunum and duodenum (ANOVA).
Table 2. Tr
everted
ansmural transport and tissue-associated aluminum in
gut preparations in response to aluminum lactate
Aluminum
tissue Transmural
N content transport
Duodenum 37°C 6 2118 788 ND
4°C 6 486 234° ND
Jejunum 37°C 6 2342 396 ND
4°C 6 788 423° ND
Results are expressed in picomoles mg wet weight. ND: non-
detectable. Aluminum lactate concentration was 370 LM (See Table I
for details).
a P < 0.001 between 37°C and 4°C; P = NS between jejunum and
duodenum (ANOVA)
Discussion
The present investigations confirm previous studies in ani-
mals and man showing that citrate markedly enhances the
absorption of aluminum from the gastrointestinal tract [18—21].
They also outline the gastrointestinal site and mechanism by
which citrate increases the absorption of aluminum. As deter-
mined by urinary aluminum excretion following gavage, ap-
proximately 40 to 50 times more aluminum was absorbed
following aluminum citrate ingestion than from other aluminum
compounds [3]. Furthermore, absorption occurs early in the
intestine with the plasma aluminum peak coinciding with the
glucose peak. This early enhancement of aluminum absorption
by citrate would be expected since citrate would be rapidly and
completely absorbed early in the small intestine and not avail-
able to enhance aluminum absorption more distally. The early
proximal absorption of citrate has also been used to explain
why calcium when given with citrate is much more effective
phosphate binder in vivo than in vitro [33].
Tissue-associated aluminum, as well as transmural move-
ment of aluminum into the serosal fluid, was studied. With
aluminum citrate, there was a prompt increase in tissue-asso-
ciated aluminum and citrate in the mucosal cells. This seemed
to be an energy-requiring process and not just non-specific
binding, since tissue levels of both citrate and aluminum could
be markedly decreased by incubation at 4°C. However, we did
not show conclusively that this represented cellular uptake by
the tissue. In association with the fall in tissue levels of citrate
at 4°C, there was a corresponding decrease in transmural
transfer of citrate. These findings would be consistent with
citrate's being taken up by mucosal cells by an energy-depen-
dent mechanism and transported into the serosal fluid. Since
C'4 citrate was measured, it is possible that rather than citrate
being directly transported into the serosal fluid, it is metabo-
lized in the intestinal cell and its metabolites are transported
into the serosal fluid. Although tissue levels of aluminum were
reduced at 4°C, the transmural movement of aluminum was
unaffected by cold. This suggests that the majority of the
transmural movement of aluminum did not occur through
cellular transport processes but rather via a paracellular path-
way. This was further supported by the fact that tissue levels of
aluminum in response to aluminum lactate were approximately
25 times as great as from aluminum citrate, and yet there was no
transmural movement of aluminum when aluminum lactate was
used. The lack of correlation between tissue aluminum content
and transcellular aluminum movement is consistent with alumi-
num moving passively into serosal fluid through paracellular
pathways. Although some investigators have suggested that
aluminum is actively transported [34, 351, they failed to account
for the insolubility of the aluminum compounds at the pH
employed. This property of aluminum chloride with the result-
ing precipitation of aluminum may overestimate the aluminum
movement.
To determine if citrate enhanced aluminum absorption
through the paracellular pathway by opening cellular tight
junctions, studies with ruthenium red and the Ussing chamber
were carried out. Ruthenium red is an electron dense substance
that does not permeate cells and can therefore be used as a
marker of tight junction structural integrity [32]. While normal
saline and aluminum chloride resulted in minimal paracellular
ruthenium red deposits, aluminum citrate was associated with
abundant ruthenium red paracellular deposits. This was espe-
cially apparent around goblet cells which are known to have
tight junctions that are more permeable than adjacent columnar
absorptive cells [36, 37]. Additional evidence supporting the
opening of the tight junctions by aluminum citrate was obtained
by using the Ussing chamber to quantitate the effect of alumi-
num citrate on transmural electrical resistance. In proximal
bowel, transmural resistance is determined by the number of
tight junction strands [36]. A reduction in resistance is synon-
ymous with a reduction in the tight junction's functional and
structural integrity [36]. In our studies, EDTA and sodium
citrate, compounds known to open tight junctions and reduce
transepithelial resistances [31], were used as positive controls
and, as expected, resulted in a prolonged reduction in electral
resistance consistent with the opening of tight junctions. Like-
wise aluminum citrate, but not aluminum chloride nor alumi-
num lactate, produced a prolonged reduction in transcellular
resistance, consistent with the opening of tight junctions.
The above findings are consistent and offer a possible expla-
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Fig. 2. Electron micrograph of isolated duodenal loops. A. Following exposure to normal saline, rare ruthenium red deposits could be seen around
goblet cells (arrows). No deposits were visible between adjacent columnar epithelial cells (magnification of x4600), B. Following aluminum citrate
exposure, dense infiltration of ruthenium red deposits could be visualized around goblet cells (arrows). The mucosal epithelium following both
normal saline and aluminum citrate was intact (magnification x3700). C. A goblet cell, at higher magnification, following aluminum citrate
treatment. Note the intense, ribbon-like outlining of the entire goblet cell's intercellular space by ruthenium red which fades away at the junction
of the columnar epithelial intercellular space (arrows) (magnification of x7600). D. Aluminum chloride pre-incubation resulted in minimal or no
ruthenium red in intercellular spaces but caused some patchy sloughings of mucosa (magnification of x4400; G, goblet cell; L, lumen; bar
represents 2 microns).
nation for the increased absorption of aluminum following
aluminum citrate therapy. We propose that at least two factors
are crucial if enhanced gastrointestinal absorption of aluminum
is to occur. First, the aluminum compound must be soluble at
the pH of the intestinal fluid, and, second, the compound under
question must result in the opening of cellular tight junctions.
These conditions are best shown by considering the three
compounds studied. Aluminum chloride is poorly absorbed
because it is insoluble at intestinal pH and does not alter the
permeability of the paracellular pathway. Aluminum lactate,
although soluble at physiological pH [3], is poorly absorbed via
the paracellular pathway because it has no effect on the
functional integrity of the tight junctions. The aluminum in
aluminum citrate, however, is soluble at physiologic pH, and by
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Fig. 3. Effect of aluminum citrate on proximal jejunal transcellular
resistance. Following an equilibration period of 10 minutes either
aluminum citrate (N 5) or sodium citrate (N = 3) was added to the
mucosal bath to achieve final concentration of 18.5 m and 55.5 mM,
respectively. Symbols are: (A) control; (•) Al citrate; (0) Na citrate.
Table 3. Determination of free calcium in the presence of aluminum
citrate, chloride or lactate
% Calcium
decrease
Free calcium
mM
Control 0% 2.25
Aluminum citrate 99.7 0.1 0.007 0.002
Aluminum chloride 19.9 0.4 1.80 0.009
Aluminum lactate No decrease 2.25
Each final aluminum concentration was 18.5 mi. Kreb's bicarbonate
solution had a calcium concentration of 2.25 m. The decrease in free
calcium occurred almost instantaneously in all cases.
complexing calcium citrate leads to the opening of cellular tight
junctions. This results in a markedly enhanced paracellular
movement of the soluble aluminum. Therefore, aluminum cit-
rate's high formation constant, which precludes the formation
of insoluble aluminum hydroxide or phosphate [26, 37] in
association with its ability to open tight junctions, probably
accounts for its high degree of gastrointestinal absorption.
Recently Provan and Yokel [381, using different and more
indirect methods, have also shown that aluminum absorption is
energy-independent and most likely occurs through the para-
cellular pathway.
Our data have important clinical implications. Since alumi-
num has a strong formation constant with citrate [26, 391,
aluminum compounds should probably not be given concomi-
tantly with citrate in any form, especially to patients with
chronic renal failure. It should also be recognized that citrate
enhances the gastrointestinal absorption of lead [40, 411 and
probably would have a similar effect for a number of other trace
elements. Because of the potential that citrate-containing com-
pounds have to enhance the gastrointestinal absorption of a
variety of environmental inorganic toxins, the long-term use of
calcium citrate [421 and potassium citrate [43] even in patients
with normal renal function needs to be re-evaluated.
0.0 4.0 8.0 12.0 16.0
Aluminum citrate, mmol/Iiter'
Fig. 4. The effect of different concentrations of aluminum citrate (0 to
18.5 mM) on free calcium in Kreb's bicarbonate solutions. Free Ca2
was quantitated using a calcium electrode. Aluminum citrate (N = 2)
effectively chelated the calcium with a ratio of 1.99:0.16 aluminum per
calcium determined when 50% of the calcium was chelated.
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